Viet Nam

Viet Nam

Expands the scope of FDI activities allowed in the pharmaceutical sector

21 Nov 2024

On 21 November 2024, Viet Nam adopted Law No. 44/2024/QH15, amending several provisions of the 2016 Law on Pharmacy. The amended law expands the scope of activities permitted for foreign-invested enterprises in the pharmaceutical sector.

Previously, such enterprises were only allowed to import drugs and pharmaceutical ingredients (excluding prohibited substances) and distribute products manufactured in Viet Nam. Under the amended law, they are now clearly permitted to engage in a broader range of activities, including:

  • the production of drugs and pharmaceutical ingredients;

  • import and export activities;

  • quality testing;

  • clinical trials and bioequivalence studies;

  • technology transfer;

  • contract manufacturing; and

  • wholesale distribution of both self-produced and imported products.

The amended law will enter into force on 1 July 2025.

Nature of measure:
  • Liberalization
Type:
  • Entry and establishment (Ownership and control)
Industry:
  • Manufacturing (Manufacture of basic pharmaceutical products and pharmaceutical preparations)
  • Services (Wholesale and retail trade)
Inward FDI:
No
Outward FDI:
No
Sources: